Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

X
Trial Profile

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Cardiovascular disorders; Embolism; Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Acronyms ETNA-AF-EU; ETNA-AF-Europe
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
  • Most Recent Events

    • 28 Aug 2023 Results (n=13164) assessing long-term effectiveness and safety of edoxaban in patients with atrial fibrillation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 28 Aug 2023 Results of sub analysis assessing of perceived versus objective frailty on outcome events in patients with AF treated with edoxaban during the 4-year follow-up of the ETNA-AF-Europe registry presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 13 Oct 2022 Results of sub analysis assessing the prevalence of frailty (Perceived vs. objective frailty) in patients with atrial fibrillation and impact on anticoagulant dosing published in the Europace
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top